Phosphagenics seeks listing on UK's AIM
Wednesday, 26 May, 2004
Melbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
The company said in a statement that it believes the listing will provide access to a more developed capital market for the company’s globally orientated healthcare products
Investment bank Williams de Broë has been appointed as nominated adviser and stockbroker for the dual listing process.
Phosphagenics last month announced the successful completion of animal studies for its transdermal delivery system for morphine. The system uses d-alpha tocopherol combined with a phosophate molecule to create an enhanced form of Vitamin E which carries morphine across the dermis.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
